{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:20Z","timestamp":1786988060933,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Initiative Program"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejmech.2019.02.036","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T02:42:04Z","timestamp":1550198524000},"page":"154-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Synthesis of new arylsulfonylspiroimidazolidine-2\u02b9,4\u02b9-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress"],"prefix":"10.1016","volume":"168","author":[{"given":"Zafar","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Morahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahreen","family":"Arooj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre N.","family":"Sobolev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1195-1659","authenticated-orcid":false,"given":"Shahid","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.02.036_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes Atlas: global estimation of the prevalence of diabetes for 2011\u20132030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2019.02.036_bib2","series-title":"Diabetes Atlas","author":"International Diabetes Federation (IDF)","year":"2017"},{"key":"10.1016\/j.ejmech.2019.02.036_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1210\/endo-83-3-572","article-title":"Grodsky, Dynamics of insulin secretion by the perfused rat pancreas","volume":"83","author":"Curry","year":"1968","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2019.02.036_bib4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/diabetes.49.11.1751","article-title":"Triggering and amplifying pathways of regulation of insulin secretion by glucose","volume":"49","author":"Henquin","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2019.02.036_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1146\/annurev.bi.64.070195.003353","article-title":"Metabolic coupling factors in pancreatic beta cell signal transduction","volume":"64","author":"Newgard","year":"1995","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/312446a0","article-title":"Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells","volume":"312","author":"Ashcroft","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.02.036_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/311271a0","article-title":"Intracellular ATP directly blocks K+ channels in pancreatic \u03b2-cells","volume":"311","author":"Cook","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.02.036_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1113\/jphysiol.1991.sp018829","article-title":"Voltage-activated calcium and potassium currents in human pancreatic beta-cells","volume":"443","author":"Kelly","year":"1991","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.ejmech.2019.02.036_bib9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1464-5491.1994.tb00302.x","article-title":"Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance","volume":"11","author":"Davies","year":"1994","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejmech.2019.02.036_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-2007-979837","article-title":"Mechanism of glycemic effects of sulfonylureas","volume":"28","author":"Ashcroft","year":"1996","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejmech.2019.02.036_bib11","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1021\/jm9810349","article-title":"Repaglinide and related hypoglycemic benzoic acid derivatives","volume":"41","author":"Grell","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib12","series-title":"Textbook of Diabetes","first-page":"462","author":"Holman","year":"1991"},{"key":"10.1016\/j.ejmech.2019.02.036_bib13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2019.02.036_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0014-4835(90)90096-D","article-title":"A\u00a0thirty year journey in the polyol pathway","volume":"50","author":"Kinoshita","year":"1990","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2019.02.036_bib15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/092986709787458362","article-title":"Aldose reductase enzyme and its implications to major health problems of 21 century","volume":"16","author":"Alexiou","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.me.26.020175.002513","article-title":"Hyperglyemia, polyol metabolism, and complications of diabetes mellitus","volume":"26","author":"Gabbay","year":"1975","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejmech.2019.02.036_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0006-3002(56)90247-5","article-title":"The mechanism of the transformation of glucose in fructose in the seminal vesicles","volume":"22","author":"Hers","year":"1956","journal-title":"Biophys. Acta."},{"key":"10.1016\/j.ejmech.2019.02.036_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.02.036_bib19","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM198805193182007","article-title":"Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications","volume":"318","author":"Brownlee","year":"1988","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.02.036_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2019.02.036_bib21","doi-asserted-by":"crossref","first-page":"33539","DOI":"10.1074\/jbc.271.52.33539","article-title":"Specifically targeted modification of human aldose reductase by physiological disulfides","volume":"271","author":"Cappiello","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/abbi.1996.0096","article-title":"Oxidized aldose reductase: in\u00a0vivo factor, not in\u00a0vitro artifact","volume":"327","author":"Grimshaw","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2019.02.036_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/138945008783431781","article-title":"Aldose reductase, still a compelling target for diabetic neuropathy","volume":"9","author":"Oates","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2019.02.036_bib24","article-title":"Analysis of the genomic region directing the expression of aldose reductase","volume":"47","author":"Nishimura","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2019.02.036_bib25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1210\/er.2003-0019","article-title":"Oxidative stress in the pathogenesis of diabetic neuropathy","volume":"25","author":"Vincent","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2019.02.036_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/dmr.5610040403","article-title":"The involvement of aldose reductase indiabetic complications","volume":"4","author":"Kinoshita","year":"1988","journal-title":"Diabetes Metab. Rev."},{"key":"10.1016\/j.ejmech.2019.02.036_bib27","first-page":"313","article-title":"Altering the course of cataracts in diabetic rats","volume":"19","author":"Fukushi","year":"1980","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2019.02.036_bib28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.182.4117.1146","article-title":"Polyolaccumulation in galactosemic and diabetic rats: control by analdose reductase inhibitor","volume":"182","author":"Dvornik","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2019.02.036_bib29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/jm00369a003","article-title":"N-[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl] thioxo met hyl] -N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor","volume":"27","author":"Sestanj","year":"1984","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF00282716","article-title":"Effect of a new aldose reductase inhibitor, (E)-3- carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on perip heral nerve disorders in streptozotocin-diabetic rats","volume":"24","author":"Kikkawa","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2019.02.036_bib31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/jm00105a018","article-title":"Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3- [[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners","volume":"34","author":"Mylari","year":"1991","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib32","first-page":"313","article-title":"Altering the course of cataracts in diabetic rats","volume":"19","author":"Fukushi","year":"1980","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejmech.2019.02.036_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1056-8727(01)00175-1","article-title":"Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients","volume":"16","author":"Asano","year":"2002","journal-title":"J.\u00a0Diabet. Complicat."},{"key":"10.1016\/j.ejmech.2019.02.036_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00024677-200403040-00006","article-title":"Clinical potential of aldose reductase inhibitors in diabetic neuropathy","volume":"3","author":"Hamada","year":"2004","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.ejmech.2019.02.036_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO;2-7","article-title":"Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches","volume":"19","author":"Costantino","year":"1999","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.02.036_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(97)80018-9","article-title":"Worldwide pharmacovigilance systems and tolerestate witdrawl","volume":"349","author":"Foppiano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2019.02.036_bib37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.53.3.580","article-title":"The effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy","volume":"53","author":"Greene","year":"1999","journal-title":"Neurology"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.ejmech.2019.02.036_bib38","first-page":"31S","article-title":"Effect of aldose reductase inhibition on the progression of nerve damage","volume":"10","author":"Greene","year":"1993","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejmech.2019.02.036_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/1056-8727(96)00113-4","article-title":"Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study, Diabetic Neuropathy Study Group in Japan","volume":"10","author":"Hotta","year":"1996","journal-title":"J.\u00a0diabetic complications"},{"key":"10.1016\/j.ejmech.2019.02.036_bib40","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0026-895X(25)14457-X","article-title":"Pharmacophor requirements of the aldose reductase inhibitor site","volume":"24","author":"Kador","year":"1983","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.02.036_bib41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/jm00155a007","article-title":"Design and synthesis of 2-(Arylamino)-4(3H)-quinazolinones as novel inhibitors of rat lens aldose reductase","volume":"29","author":"DeRuiter","year":"1986","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00706-011-0600-9","article-title":"Synthesis, characterization, and hypoglycemic activity of 3-(arylsulfonyl)spiroimidazolidine-2,4-diones","volume":"143","author":"Iqbal","year":"2012","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejmech.2015.05.011","article-title":"Synthesis, characterization, hypoglycemic and aldose reductase inhibition activity of arylsulfonylspiro[fluorene-9,5\u02b9-imidazolidine]-2\u02b9,4\u02b9-diones","volume":"98","author":"Iqbal","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3998\/ark.5550190.0009.g29","article-title":"Synthesis and hypoglycemic activity of 5,5-dimethylarylsulfonylimidazolidine-2,4-diones","author":"Kashif","year":"2008","journal-title":"Arkivoc xvi"},{"key":"10.1016\/j.ejmech.2019.02.036_bib45","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/BF00401058","article-title":"Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucosestimulated insulin secretion similar to those of normal islets","volume":"36","author":"Ishihara","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2019.02.036_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/endo-127-1-126","article-title":"Establishment of a pancreatic beta-cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms","volume":"127","author":"Miyazaki","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2019.02.036_bib47","first-page":"19","article-title":"Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites","volume":"4","author":"El-Kabbani","year":"1998","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejmech.2019.02.036_bib48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bmcl.2012.11.039","article-title":"Dual action spirobicycloimidazolidine-2,4-diones: antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications","volume":"23","author":"Iqbal","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.02.036_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0969-2126(97)00216-5","article-title":"\u2018specificity\u2019pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil","volume":"5","author":"Urzhumtsev","year":"1997","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2019.02.036_bib50","doi-asserted-by":"crossref","first-page":"16134","DOI":"10.1021\/bi9717136","article-title":"The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant","volume":"36","author":"Harrison","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.02.036_bib51","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/j.bmc.2005.12.032","article-title":"New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies","volume":"14","author":"Farid","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1747-0285.2005.00327.x","article-title":"Use of an induced fit receptor structure in virtual screening","volume":"67","author":"Sherman","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2019.02.036_bib53","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1021\/jm990502r","article-title":"A\u00a0potent aldose reductase inhibitor,(2 S, 4 S)-6-Fluoro-2\u2018, 5 \u2018-dioxospiro [chroman-4, 4 \u2018-imidazolidine]-2-carboxamide (fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography","volume":"43","author":"Oka","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/prot.20015","article-title":"Ultrahigh resolution drug design I: details of interactions in human aldose reductase\u2013inhibitor complex at 0.66 \u00c5","volume":"55","author":"Howard","year":"2004","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"key":"10.1016\/j.ejmech.2019.02.036_bib55","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/prot.20001","article-title":"Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors","volume":"55","author":"El-Kabbani","year":"2004","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"key":"10.1016\/j.ejmech.2019.02.036_bib56","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1248\/bpb.27.1584","article-title":"Effects of ellagic acid and 2-(2,3,6-Trihydroxy-4-carboxyphenyl)ellagic acid on sorbitol accumulation in\u00a0vitro and in\u00a0vivo","volume":"27","author":"Ueda","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2019.02.036_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000056094","article-title":"Pharmacological properties of fidarestat, a Potent Aldose Reductase Inhibitor, clarified by using sorbitol in human and rat erythrocytes","volume":"62","author":"Sobajimaa","year":"2001","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejmech.2019.02.036_bib58","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1016\/j.bmc.2008.03.039","article-title":"Carboxymethylatedpyridoindole antioxidants as aldose reductase inhibitors: synthesis, activity, partitioning, and molecular modelling","volume":"16","author":"Stefek","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib59","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0021-9258(17)45256-2","article-title":"Isolation and properties of lens aldose reductase","volume":"240","author":"Hayman","year":"1965","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib60","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1021\/jm070398a","article-title":"Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity","volume":"50","author":"La Motta","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.036_bib61","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0026-0495(85)90223-9","article-title":"Properties of ICI 128,436 a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat","volume":"4","author":"Stribling","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2019.02.036_bib62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1254\/jjp.60.133","article-title":"Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in\u00a0vitro and on diabetic neuropathy and cataract formation in rats","volume":"73","author":"Ashizawa","year":"1997","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.02.036_bib63","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1021\/bi00189a019","article-title":"Mechanism of aldose reductase inhibition: binding of NADP+\/NADPH and alrestatin-like inhibitors","volume":"33","author":"Ehrig","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.02.036_bib64","doi-asserted-by":"crossref","first-page":"12761","DOI":"10.1039\/C5RA25984C","article-title":"Multifunctional aldose reductase inhibitors based on 2H-benzothiazine 1,1-dioxide","volume":"6","author":"Han","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2019.02.036_bib65","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1021\/jm050412o","article-title":"Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity","volume":"48","author":"El-Kabbani","year":"2005","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419301503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419301503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:47:18Z","timestamp":1759326438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419301503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":65,"alternative-id":["S0223523419301503"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.036","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of new arylsulfonylspiroimidazolidine-2\u02b9,4\u02b9-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}